Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review

Executive Summary

Wyeth is sending letters to approximately 550,000 physicians as part of a Prempro risk management program to address risks associated with use of the hormone combination for cardiovascular disease and osteoporosis prevention

Related Content

Effexor Follow-On Will Launch One Year Before XR Patent Expires, Wyeth Says
Premarin WHI Results Support Short-Term Use, Wyeth And Investigators Agree
Cancer Consumer Groups Oppose Oncologic Surrogates Citing WHI Experience
Wyeth Prempro Gets Dementia Warning; FDA Considering HRT Class Labeling
Wyeth Dual HRT Launch: Low-Dose Premarin, Prempro Available This Summer
Galen Femring Includes HRT Class Labeling; Launch In June
Pfizer Asks Supreme Court To Protect “Right Of Reply” In Cases Like ALLHAT
HRT clinical evaluation guidance
Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March
Wyeth Cost-Cutting Will Spare Effexor, Manufacturing Investments



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts